SmartMed Technologies announces Endo Tanaka as Head of Macro Research

SmartMed Technologies of South Korea today announced that Endo Tanaka has joined the firm as Head of Macro Research.

Online PR News – 07-February-2020 – Yeongdeungpo-gu/SEOUL – In this newly created role, Endo Tanaka will lead research activity across SmartMed Technologies' medical investment platform.

With responsibility for research, Endo will make a key contribution to the firm, heading the micro research division, providing portfolio managers with investable ideas across all asset classes. In addition, Endo Tanaka will play a prominent role in presenting investment views to the Board of SmartMed Technologies.

SmartMed Technologies' Chief Executive Officer, Mr. Hyung-min Joon commented on the welcome addition saying "I am delighted to welcome a professional of Endo's calibre to the firm. Having a powerful global research function gives our investment teams a crucial edge as they strive to deliver superior performance to our clients. Endo will help us to make optimal use of our global research resources as well as the best external research."

Endo Tanaka was most recently Head of Macro Strategy at Sumitomo Mitsui Financial Group. Before that, he served as Head of Research for Emerging Markets for Resona Holdings across different asset classes.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.